证券记录 · 已归档季度
FOLD
Amicus Therapeutics, Inc. · Healthcare · Biotechnology
11被追踪持有人
—Δ持有人
38.85M持有股份
$385.40M报告持仓市值
+0新建仓位
−0清仓
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q2 2024
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q1 2026 | 106 | -6 | 206.15M | $2.98B | +6 | −13 |
| Q4 2025 | 112 | +4 | 192.14M | $2.74B | +5 | — |
| Q3 2025 | 19 | -1 | 150.66M | $1.19B | — | −2 |
| Q2 2025 | 18 | 0 | 135.88M | $778.62M | — | — |
| Q1 2025 | 15 | +2 | 70.64M | $576.46M | +2 | — |
| Q4 2024 | 13 | -1 | 63.65M | $599.56M | — | −1 |
| Q3 2024 | 13 | +2 | 42.84M | $457.59M | +2 | — |
| Q2 2024 | 11 | — | 38.85M | $385.40M | — | — |
持有人 · Q2 2024
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 21.11M | — | $209.39M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Wellington Management ✦ | 21.11M | — | $209.39M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Wellington Management ✦ | 21.11M | — | $209.39M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Wellington Management ✦ | 21.11M | — | $209.39M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 21.11M | — | $209.39M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 21.11M | — | $209.39M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 21.11M | — | $209.39M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Geode Capital Management ✦ (被动) | 6.52M | — | $64.68M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Geode Capital Management ✦ (被动) | 6.52M | — | $64.68M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 3.02M | — | $29.93M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Citadel Advisors ✦ | 3.02M | — | $29.93M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Norges Bank ✦ (被动) | 2.92M | — | $29.01M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Millennium Management ✦ | 1.89M | — | $18.79M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | T. Rowe Price ✦ | 1.39M | — | $13.79M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | T. Rowe Price ✦ | 1.39M | — | $13.79M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | PRIMECAP Management ✦ | 1.05M | — | $10.44M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | Renaissance Technologies ✦ | 632.02K | — | $6.27M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | Two Sigma Investments ✦ | 135.50K | — | $1.34M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | D. E. Shaw & Co. ✦ | 89.28K | — | $885,608 | 0.0% | n/c | 1 | SEC ↗ |
| 20 | AQR Capital Management ✦ | 87.62K | — | $869,230 | 0.0% | n/c | 1 | SEC ↗ |
| 21 | AQR Capital Management ✦ | 87.62K | — | $869,230 | 0.0% | n/c | 1 | SEC ↗ |
"持仓权重"= 该持仓占该管理人已申报13F股权价值的比例——即信念度衡量指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 296 持有人, 325.04M 股份, $4.48B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
该证券的被追踪持有人最常同时持有的其他证券——基于共同持有计数，而非基本面关联。
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q2 2024 ·
方法论 ·
通过API获取此数据